ARCA biopharma to Present at 27th Annual JPMorgan Healthcare ...(constitute an offer to sell or the solic...)

Date:1/8/2009

constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Nuvelo, ARCA and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus/consent solicitation described above, as supplemented. Additional information regarding the directors and executive officers of Nuvelo is also included in Nuvelo's proxy statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April 23, 2008 and its Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the SEC on March 12, 2008. These documents are available as described above.

'/>"/>

SOURCE ARCA biopharma, Inc. and Nuvelo, Inc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. Helix BioPharma Announces Q1 2009 Financial Results
4. McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries
5. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
6. XTL Biopharmaceuticals Implements Restructuring Plan
7. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
8. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
9. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
10. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
11. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission